Navigation Links
Regeneron Announces Presentation at the Bank of America Merrill Lynch 2011 Health Care Conference
Date:5/2/2011

TARRYTOWN, N.Y., May 2, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast its presentation at the Bank of America Merrill Lynch 2011 Health Care Conference on Tuesday, May 10, 2011 at 9:20 a.m. Pacific Time (12:20 p.m. Eastern Time).  The session may be accessed through the Company's web site, www.regeneron.com, on the Investor Relations page.  An archived version of the presentation will be available after the live webcast through May 27, 2011.  

Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions.  In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in Phase 3 clinical trials for the potential treatment of gout, diseases of the eye (wet age-related macular degeneration, central retinal vein occlusion, and diabetic macular edema), and certain cancers.  Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions, and cancer.  Additional information about Regeneron and recent news releases are available on Regeneron's web site at www.regeneron.com.Contact Information:Michael Aberman, M.D.

Peter DworkinInvestor Relations

Corporate Communications914.345.7799

914.345.7640michael.aberman@regeneron.com

peter.dworkin@regeneron.com
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Second Phase 3 Study in Central Retinal Vein Occlusion
2. Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema
3. Regeneron Announces Presentation at the 10th Annual Needham Healthcare Conference
4. Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer
5. Regeneron Announces March 2011 Investor Conference Presentations
6. Regeneron Submits Biologics License Application to FDA for VEGF Trap-Eye for Treatment of Wet Age-Related Macular Degeneration
7. Regeneron Reports Full Year and Fourth Quarter 2010 Financial and Operating Results
8. Regeneron to Webcast Investor Briefing on VEGF Trap-Eye Clinical Program on Sunday, February 13th at 9 am ET
9. Regeneron Announces Presentation at the ISI Annual Conference
10. Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME)
11. Regeneron Schedules December 20, 2010 Teleconference and Webcast to Discuss Results of VEGF Trap-Eye Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and Phase 2 Study in Diabetic Macular Edema (DME)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... , Sept. 29, 2014  Repeated exposure to broad-spectrum ... associated with early childhood obesity, say researchers from The ... a retrospective study based on data from electronic health ... The researchers found that children with four or ... particularly more likely to be at risk for obesity. ...
(Date:9/29/2014)... CHICAGO , Sept. 29, 2014 ... clinical trials are conducted according to good clinical ... the HOPA Investigational Drug Service Best Practice Standards, ... best practice standards and guidance for pharmacists and ... Drug Service Best Practice Standards emphasizes the critical ...
(Date:9/29/2014)... 29, 2014 EU5 Capsule Endoscopy Systems Market ... GlobalData,s new report, "EU5 Capsule Endoscopy Systems Market Outlook ... Capsule Endoscopy Systems market. The report provides value, in ... prices (in US dollars) within market segments - Capsule ... The report also provides company shares and ...
Breaking Medicine Technology:Antibiotic Use by Age 2 Associated with Obesity Risk 2Antibiotic Use by Age 2 Associated with Obesity Risk 3HOPA Introduces First Investigational Drug Service Best Practice Standards For Institutions And Infusion Clinics 2HOPA Introduces First Investigational Drug Service Best Practice Standards For Institutions And Infusion Clinics 3EU5 Capsule Endoscopy Systems Market Outlook to 2020 2EU5 Capsule Endoscopy Systems Market Outlook to 2020 3
... 2011 PAREXEL International Corporation (NASDAQ: PRXL ... and fiscal year ended June 30, 2011.   ... consolidated service revenue increased by 5.2% to $310.5 million ...  Excluding the positive impact from foreign exchange movements in ...
... is a law that requires healthcare organizations to convert medical ... at the forefront of many leading managed hosting providers. INetU ... and HITECH compliance, has been asked to address these concerns ... session on Wednesday, August 10. "The HITECH Act ...
Cached Medicine Technology:PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results 2PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results 3PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results 4PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results 5PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results 6PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results 7PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results 8PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results 9PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results 10PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results 11PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results 12PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results 13HITECH Act Puts Security of Electronic Medical Records in Hands of Hosting Providers 2
(Date:9/30/2014)... (PRWEB) September 30, 2014 AutoTex ... sporting the iconic pink ribbon in support of breast ... popular month for businesses and non-profits to “go pink” ... cause. , AutoTex PINK is a woman-owned company that ... They are committed to partnering with their customers ...
(Date:9/30/2014)... Minneapolis, MN (PRWEB) September 30, 2014 ... recognized leader in business technology and services was ... in First Call Effectiveness (FCE) in 2013. This ... devices properly the first time and for an ... longevity. For more than 20 years BEI Services ...
(Date:9/30/2014)... Julie Kuriakose, MD; Physician, ... will discuss how restaurants can become more allergy-friendly and ... restrictions at the 2014 Allergy Eats Food Allergy ... 21 in New York City. , “I’m extremely delighted ... such an engaged industry audience. As food allergies become ...
(Date:9/30/2014)... Up to 45% of the population snores ... have sleep apnea. Of these, only 10% have been ... tolerate their prescribed medical device known as CPAP (continuous ... which supports the airway during sleep. , In today’s ... and increasingly difficult to get. Snoring and sleep apnea ...
(Date:9/30/2014)... compared with placebo did not reduce hospital length of ... mortality, or the risk of death at 6 months ... ill, according to a study published in JAMA ... coincide with its presentation at the European Society of ... prevalence of low vitamin D levels has been confirmed ...
Breaking Medicine News(10 mins):Health News:Change Your Blades … Change A Life! AutoTex PINK Wiper Blades Are Helping Wipe Out Breast Cancer 2Health News:Change Your Blades … Change A Life! AutoTex PINK Wiper Blades Are Helping Wipe Out Breast Cancer 3Health News:Loffler Companies Rated Number One Among U.S. Dealers in Service “First Call Effectiveness” 2Health News:Loffler Companies Rated Number One Among U.S. Dealers in Service “First Call Effectiveness” 3Health News:Hudson Allergy’s Dr. Julie Kuriakose to Speak at Prestigious Food Allergy Conference in New York City 2Health News:Hudson Allergy’s Dr. Julie Kuriakose to Speak at Prestigious Food Allergy Conference in New York City 3Health News:Snoring: Robs People and Their Bed Partners of the Rest They Need to Face Daily Challenges 2Health News:Snoring: Robs People and Their Bed Partners of the Rest They Need to Face Daily Challenges 3Health News:High-dose vitamin D for ICU patients who are vitamin D deficient does not improve outcomes 2
... when choosing mates, study finds , MONDAY, June 29 (HealthDay ... a mate, according to a U.S. study that challenges the ... recruited 350 undergraduates for speed-dating events. In half the events, ... in one location. The roles were reversed in the other ...
... ... their perspectives on eye care and safety. , ... Minneapolis, MN (PRWEB) June 29, 2009 -- Stop squinting…proper eye care and ... displays in all their brilliance and clarity., , , The Healthcare Scoop , in recognition ...
... , Two MuGard US Patents Issued , , DALLAS, ... (OTC Bulletin Board: ACCP), announced today that its European partner, ... MuGard in Greece. This follows previous ... license from Access Pharmaceuticals, SpePharm is responsible for manufacturing, regulatory ...
... Corporation (Nasdaq: AIRM ), the largest air medical ... a petition with the National Transportation Safety Board (NTSB) requesting ... June 29, 2008 mid-air collision accident in Flagstaff, Arizona. ... to see and avoid the other helicopter on approach to ...
... identified and described a mechanism whereby a single-base change in ... The focus in this study was on a common ... only a slightly increased risk of cancer. However, the risk ... and by almost 100% of African populations. The high ...
... particular can gene raise a man,s risk of familial, or ... disease, according to new research by scientists at the National ... to be identified that affects the risk of familial testicular ... The study appears in the July 2009 Cancer ...
Cached Medicine News:Health News:Maybe Men Aren't So Picky After All 2Health News:The Healthcare Scoop Community Says 'Eye Care' 2Health News:The Healthcare Scoop Community Says 'Eye Care' 3Health News:Access Pharmaceuticals Announces Commercial Launch of MuGard(TM) in Greece by SpePharm 2Health News:Access Pharmaceuticals Announces Commercial Launch of MuGard(TM) in Greece by SpePharm 3Health News:Air Methods Petitions NTSB for Reconsideration of Probable Cause Determination 2Health News:Risk of cancer 2Health News:Second gene linked to familial testicular cancer 2Health News:Second gene linked to familial testicular cancer 3
... design permits continuous irrigation through ... the Foley Catheter. 3-Way Catheters ... as well as LUBRICATH coatings, ... of models including Suggs, Emmett, ...
All-silicone construction provides maximum softness and biocompatibility for enhanced patient comfort. Supplied sterile in peel-open packages. Intended for one-time use....
Used to provide bladder drainage by percutaneous placement of a balloon catheter. Supplied sterile in peel-open packages. Intended for one-time use....
Used for injection into urethral strictures, bladder neck contracture, and the bladder wall. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: